Abstract
Surgery followed by chemoradiation and adjuvant chemotherapy is standard of care for patients with a glioblastoma (GBM). Due to its limited benefit, an upfront method to predict dismal outcome would prevent unnecessary toxic treatment. We searched for a predictive blood derived biomarker in a cohort of 55 patients with GBM. Increasing age (HR 1.03, 95 % CI 1.01-1.06), and postoperative tumor residue (HR 1.07, 95 % CI 1.02-1.15) were independently associated with unfavourable progression free survival (PFS) in these patients. Corticosteroid use before start of chemoradiaton was strongly predictive for outcome (HR 3.26, 95 % CI 1.67-6.39) with a mean PFS and OS in patients using corticosteroids of 7.3 and 14.6 months, versus 16.1 and 21.6 months in patients not using corticosteroids (p = 0.0005, p < 0.0067 respectively). Despite earlier reports, blood concentrations of YKL-40, Fetuin-a and haptoglobin were not predictive for response. In addition, serum peptide profiles, determined by MALDI-TOF mass spectroscopy, were not predictive as well. In conclusion, further biomarker discovery studies are needed to predict treatment outcome for patients with GBM in the near future.
Original language | English |
---|---|
Pages (from-to) | 221-30 |
Number of pages | 10 |
Journal | Journal of Neuro-Oncology |
Volume | 129 |
Issue number | 2 |
DOIs | |
Publication status | Published - Sept 2016 |
Keywords
- Adolescent
- Adrenal Cortex Hormones/blood
- Adult
- Aged
- Blood Platelets/pathology
- Brain Neoplasms/blood
- Chemoradiotherapy/methods
- Chitinase-3-Like Protein 1/blood
- Cohort Studies
- Disease-Free Survival
- Female
- Glioblastoma/blood
- Haptoglobins/metabolism
- Humans
- Male
- Middle Aged
- Outcome Assessment, Health Care
- Proteomics
- Treatment Outcome
- Young Adult
- alpha-2-HS-Glycoprotein/metabolism